Therapeutics News and Research

RSS

Focused ultrasound can be safely used in children being treated for brain cancer

Columbia University researchers are the first to show that focused ultrasound - a non-invasive technique that uses sound waves to enhance the delivery of drugs into the brain - can be safely used in children being treated for brain cancer.

19 Nov 2025

Cancer cells hijack cell death enzyme to regrow after treatment

The emergence of cancer drug resistance remains one of the most pressing problems in cancer care and there is a critical need to devise approaches to mitigate it.

19 Nov 2025

Deformability helps cancer cells squeeze through tight tissue gaps, study shows

Aggressive cancer cells are masters of movement. When they spread through the body, they cause metastasis, which significantly reduces a person's chance of survival.

18 Nov 2025

UCI Health launches clinical trial to test investigational cell therapy for lupus

UCI Health has opened a clinical trial to test an investigational cell therapy for lupus with the potential to give patients long-term remission of symptoms.

17 Nov 2025

New malaria treatment holds promise against rising drug resistance

The first new malaria treatment in decades holds promise against rising drug resistance after Swiss drugmaker Novartis announced it was as effective at treating the disease as established treatments.

17 Nov 2025

DeepTarget: A new tool for drug repurposing in oncology

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

14 Nov 2025

New insights into periodontitis reveal gender-specific inflammatory mechanisms

A study out of the University of North Carolina at Chapel Hill has unveiled new insights into the inflammatory processes behind periodontitis, a common and debilitating gum disease. Research conducted by UNC Adams School of Dentistry's Julie Marchesan, DDS, PhD, and UNC School of Medicine's Jenny Y. Ting, PhD, found that a part of the immune system called the inflammasome plays a key role in disease development, and that blocking this system prevents bone resorption only in males.

14 Nov 2025

New insights into glioblastoma survival linked to brain fluid dynamics

Glioblastoma-the most aggressive form of brain cancer-remains one of medicine's biggest challenges. Despite surgery, radiotherapy, and chemotherapy, most patients survive only about a year after diagnosis.

14 Nov 2025

Exploring m6A RNA modification as a therapeutic target in cardiovascular disorders

Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of cardiovascular diseases (CVDs).

14 Nov 2025

Transforming colorectal cancer research with patient-derived xenograft models

Patient-derived xenograft (PDX) models are emerging as a transformative tool in colorectal cancer (CRC) research, offering unparalleled insights into tumor biology, drug resistance, and personalized treatment approaches.

14 Nov 2025

Pig kidney transplant breakthrough uncovers immune rejection secrets

Researchers have uncovered and then overcome an obstacle that has led to the failure of pioneering efforts in xenotransplantation, in which an animal kidney is transplanted into a human.

13 Nov 2025

Cellarity's AI model predicts drug-induced liver injury

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the publication of a seminal manuscript in Nature Communications, which describes a novel framework for the prediction and characterization of drug-induced liver injury (DILI), along with open-source posting of the model and validation data.

13 Nov 2025

Research identifies factors for long-term myeloma remission

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner.

13 Nov 2025

TRIMTECH Therapeutics appoints Dr Mike Hutton to Scientific Advisory Board

TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the appointment of Dr Mike Hutton to its Scientific Advisory Board (SAB).

From TRIMTECH Therapeutics 12 Nov 2025

Collaborative effort advances next-generation therapies for pancreatic and GI cancers

Last year, researchers at the University of California, Riverside, developed a novel "molecular crowbar" strategy to degrade the oncogenic enzyme Pin1, a protein that is overexpressed in many tumors including pancreatic cancer.

12 Nov 2025

Breakthroughs in theranostic nanomaterials for traumatic brain injury management

Traumatic brain injury (TBI) remains one of the most pressing public health challenges, leaving millions with lasting disabilities each year.

12 Nov 2025

Potential breakthrough in treating acute kidney injury with ceramide-targeting drugs

Serious damage to short-term kidney function-known as acute kidney injury, or AKI-can be fatal and also increase the risk of irreversible chronic kidney disease. It can be triggered by stressors ranging from sepsis to heart surgery, and it affects more than half of ICU patients.

12 Nov 2025

New discovery reveals crucial link between cholesterol and breast cancer progression

Cancer Center at Illinois (CCIL) Program Leader Erik Nelson's lab made an important discovery about the relationship between cholesterol and breast cancer progression with crucial implications for breast cancer therapeutics.

11 Nov 2025

The caffeine conundrum in rapid depression treatments

Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic dissection of rapid antidepressant action identifies adenosine as the critical mediator, yet adenosine receptors are the primary target of caffeine, the world's most widely consumed psychoactive substance.

11 Nov 2025

Nanoparticle vaccine eliminates HPV-induced tumors in animal model

A nanoparticle vaccine designed to fight cancers induced by human papillomavirus (HPV) eradicated tumors in an animal model of late-stage metastatic disease, UT Southwestern Medical Center scientists report in a new study published in the Proceedings of the National Academy of Sciences (PNAS).

11 Nov 2025